Health
15 Oct 2026
Ultragenyx Raises Significant Capital from Priority Review Voucher Sales
The biotech company sold two priority review vouchers earned through recent gene‑therapy approvals, boosting its balance sheet.
Read moreTopic
#Angelman syndrome
1 story